Title: Insomnia Drug Target and Market Forecast to 2023
1EpiCast Report Insomnia Epidemiology Forecast
to 2023 By RnRMarketResearch
- Browse more reports on Pharmaceuticals at
http//www.rnrmarketresearch.com/reports/life-scie
nces/pharmaceuticals
http//www.rnrmarketresearch.com/
sales_at_RnRMarketResearch.com 1 888 391 5441
2Insomnia Epidemiology Forecast to 2023
- GlobalData epidemiologists used comprehensive
country-specific data from population-based
studies published in peer-reviewed journal
articles to arrive at a meaningful, in-depth
analysis and forecast for the total prevalent
cases of acute insomnia, chronic insomnia (not
fulfilling DSM-IV criteria), chronic primary
insomnia, and chronic secondary insomnia in the
7MM, based on the DSM-IV criteria. For all the
7MM, the total prevalent cases of acute insomnia,
chronic insomnia (not fulfilling DSM-IV
criteria), chronic primary insomnia, and chronic
secondary insomnia were segmented by age and sex,
which facilitates an understanding of the
distribution of the disease within the population
and informs strategies to improve the management
of the disease. - Complete report available at http//www.rnrmarketr
esearch.com/epicast-report-insomnia-epidemiology-f
orecast-to-2023-market-report.html .
http//www.rnrmarketresearch.com/
sales_at_RnRMarketResearch.com 1 888 391 5441
3Insomnia Epidemiology Forecast to 2023
GlobalData epidemiologists forecast that the
total prevalent cases of acute insomnia in the
7MM will increase from 121,799,911 total
prevalent cases in 2013, to 130,482,156 total
prevalent cases in 2023 at an Annual Growth Rate
(AGR) of 0.71. GlobalData epidemiologists
forecast an increase in the total prevalent cases
of chronic insomnia (not fulfilling DSM-IV
criteria) in the 7MM from 62,982,390 total
prevalent cases in 2013, to 67,471,957 total
prevalent cases in 2023 at an AGR of 0.71. The
7MM had an estimated 23,690,040 total prevalent
cases of chronic primary insomnia in 2013 and the
number of total prevalent cases is expected to
increase to 25,378,728 by 2023, at an AGR of
0.71. (This is a premium report priced at
US3995 for a single user License.)
http//www.rnrmarketresearch.com/
sales_at_RnRMarketResearch.com 1 888 391 5441
4Insomnia Epidemiology Forecast to 2023
- Scope
- The insomnia epidemiology report is written and
developed by Mastersand PhD-level
epidemiologists. - The EpiCast Report is in-depth, high quality,
transparent and market-driven, providing expert
analysis of disease trends in the 7MM. - The Insomnia EpiCast Report provides an overview
of the risk factors, comorbidities, and the
global and historical trends for insomnia in the
seven major markets (7MM) (US, France, Germany,
Italy, Spain, UK, and Japan). It includes a
10-year epidemiological forecast for the total
prevalent cases of acute insomnia, chronic
insomnia (not fulfilling DSM-IV criteria),
chronic primary insomnia, and chronic secondary
insomnia, segmented by sex and age (in 15-year
age groups beginning at 15 years and ending at
75 years) in these markets.
http//www.rnrmarketresearch.com/
sales_at_RnRMarketResearch.com 1 888 391 5441
5Insomnia Epidemiology Forecast to 2023
- Reasons to Buy
- Develop business strategies by understanding the
trends shaping and driving the global insomnia
market. - Quantify patient populations in the global
insomnia market to improve product design,
pricing, and launch plans. - Organize sales and marketing efforts by
identifying the sex and age groups that present
the best opportunities for insomnia therapeutics
in each of the markets covered.
http//www.rnrmarketresearch.com/
sales_at_RnRMarketResearch.com 1 888 391 5441
6Insomnia Epidemiology Forecast to 2023
- For more details contact Mr. Ritesh Tiwari
sales_at_rnrmarketresearch.com / 18883915441
RnRMarkertResearch RnRMarketResearch.com, an
online repository of market research reports,
offers in-depth analysis of over 5000 market
segments. RnR Market Research library has
syndicated reports by leading market research
publishers across the globe.
http//www.rnrmarketresearch.com/
sales_at_RnRMarketResearch.com 1 888 391 5441